Strategy for NHIA Drug Expenditure Target：A Case Study of Statin drug

• Main Authors: Chen, Chien Hong, 陳健鴻
• Other Authors: Lin, Shu-Jou
• Format: Others
• Language: zh-TW
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/90041565744505325137

碩士 === 國立臺灣師範大學 === 高階經理人企業管理碩士在職專班(EMBA) === 104 === Taiwan National Health Insurance was admired in the world. Among the total expenses of insurance payment, about a quarter is drug expenses. Under this health care system, National Health Insurance Administration is a monopsony and imposes strict control on drug price. It is well-known that drug pricing of newly developed drugs is lower than the overall top ten advanced countries. Therefore, many pharmaceutical companies decide to delay or even abandon the launch of new drugs in Taiwan. This study seeks to investigate the strategy implications for pharmaceutical companies of second generation health insurance law in 2013 with a particular focus on the impacts of the implementation of drugs cost allocation ratio target system. Among various drugs covered in the insurance program, this study focuses on the lipid-lowering drugs and drugs with lipid-lowering drugs in the largest proportion of Statin drugs for the study of the subject. This study mainly uses IMS data to probe our research inquiries. Interviews information is also included as supplementary evidence. Keywords: Statin drugs, Original pharmaceutical companies, Drug. Expenditure Target